- Previous Close
25.00 - Open
25.00 - Bid 24.55 x --
- Ask 24.85 x --
- Day's Range
24.40 - 25.25 - 52 Week Range
19.00 - 53.00 - Volume
51,719 - Avg. Volume
79,103 - Market Cap (intraday)
1.63B - Beta (5Y Monthly) 1.64
- PE Ratio (TTM)
59.29 - EPS (TTM)
0.42 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
39.00
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics for customers in the pharmaceutical and research industries. The company provides FabALACTICA, a cysteine protease; FabRICATOR, a cysteine protease; and FabRICATOR Z, for the digestion of mouse IgG2a and IgG3, and generating a homogenous pool of F(ab')2 and Fc fragments. It offers FabULOUS (SpeB), a cysteine protease; GingisKHAN, a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. In addition, the company offers GingisREX, a protease that digests proteins C-terminally of arginine residues; GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; and OpeRATOR, an O-glycan-specific protease. Further, it provides OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; GlycOCATCH, an affinity resin; GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a goat polyclonal antibody; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody. Additionally, the company offers antibodies, assay kits, reagents, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services, as well as operates an online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Europe, North America, and Asia. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.
www.genovis.comRecent News: GENO.ST
View MorePerformance Overview: GENO.ST
Trailing total returns as of 1/17/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GENO.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GENO.ST
View MoreValuation Measures
Market Cap
1.64B
Enterprise Value
1.59B
Trailing P/E
59.52
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.62
Price/Book (mrq)
7.37
Enterprise Value/Revenue
12.28
Enterprise Value/EBITDA
29.00
Financial Highlights
Profitability and Income Statement
Profit Margin
13.49%
Return on Assets (ttm)
6.03%
Return on Equity (ttm)
8.75%
Revenue (ttm)
127.86M
Net Income Avi to Common (ttm)
17.25M
Diluted EPS (ttm)
0.42
Balance Sheet and Cash Flow
Total Cash (mrq)
135.81M
Total Debt/Equity (mrq)
37.33%
Levered Free Cash Flow (ttm)
13.69M